Evidence map›Paper›PMID 37887569›Full record

SynthesisCurrent oncology (Toronto, Ont.)2023

A Meta-Analysis of Randomized Clinical Trials Assessing the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer.

Zakaria Alameddine, Muhammad Rafay Khan Niazi, Anisha Rajavel, Jai Behgal, Praneeth Reddy Keesari, Ghada Araji, Ahmad Mustafa, Chapman Wei, Abdullah Jahangir, Terenig O Terjanian

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zakaria AlameddineStaten Island University Hospital, Staten Island, NY 10305, USA.ORCID 0009-0004-3605-3806
Muhammad Rafay Khan NiaziStaten Island University Hospital, Staten Island, NY 10305, USA.ORCID 0000-0002-4615-3147
Anisha RajavelStaten Island University Hospital, Staten Island, NY 10305, USA.
Jai BehgalStaten Island University Hospital, Staten Island, NY 10305, USA.
Praneeth Reddy KeesariStaten Island University Hospital, Staten Island, NY 10305, USA.
Ghada ArajiStaten Island University Hospital, Staten Island, NY 10305, USA.
Ahmad MustafaStaten Island University Hospital, Staten Island, NY 10305, USA.
Chapman WeiStaten Island University Hospital, Staten Island, NY 10305, USA.
Abdullah JahangirUniversity of Oklahoma Health Sciences Center, Oklahoma, OK 73104, USA.
Terenig O TerjanianStaten Island University Hospital, Staten Island, NY 10305, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer ranks as the second most common malignancy in males. Prostate cancer progressing on androgen deprivation therapy (ADT) is castration-resistant prostate cancer (CRPC). Poly-ADP ribose polymerase (PARP) inhibitors (PARPis) have been at the forefront of the treatment of CRPC. We aim to better characterize the progression-free survival (PFS) and overall survival (OS) in metastatic CRPC patients treated with PARPis. A systemic review search was conducted using National Clinical Trial (NCT), PubMed, Embase, Scopus, and Central Cochrane Registry. The improvement in overall survival was statistically significant, favoring PARPis (hazard ratio (HR) 0.855; 95% confidence interval (CI) 0.752-0.974;

Indexed as

Poly(ADP-ribose) Polymerase InhibitorsProstatic Neoplasms, Castration-ResistantAndrogen AntagonistsHumansMaleProgression-Free SurvivalRandomized Controlled Trials as TopicAndrogen AntagonistsPoly(ADP-ribose) Polymerase Inhibitorscastrate-resistant prostate cancerhomologous recombination repair genesoverall survivalPARP inhibitorsprogression-free survival

Identifiers

PMID37887569
PMCPMC10605202

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.